Search Results

cervical lymph node metastases from papillary carcinoma of the thyroid . Br J Surg 2001 ; 88 : 1241 – 1244 . 21. Machens A Hinze R Thomusch O Dralle H . Pattern of nodal metastasis for primary and reoperative thyroid cancer . World J Surg

in patients with and without brain metastases, and has less toxicity than either the first- or second-generation EGFR TKIs. Virtually all patients who experience response to frontline EGFR TKI therapy develop resistance. The most common mechanism of

not. 3 , 5 In addition, brain metastases have historically been associated with a poorer prognosis and have been highly underrepresented in existing randomized trials ( Table 1 ); whether these patients receive the same benefit from local therapy as

adopting a multimodal approach consisting of neoadjuvant systemic chemotherapy followed by consolidative surgical resection in patients presenting with bulky/locally advanced nodal metastases from penile cancer. In 2013, an estimated 1570 new cases of

.5%; P =.01), or distant metastases (1.8% vs 9.5%; P =.029) vs HPV-negative patients. Among HPV-positive patients, 75.5%, 12.7%, and 10.9% had squamous cell carcinoma NOS, basaloid squamous cell carcinoma, and squamous cell carcinoma large cell non

; 233 : 537 – 541 . 39 Fourquet A de la Rochfordiere A Campana F . Occult primary breast cancer with axillary metastases . In Harris JR , Lippman ME , Morrow M , Hellman S (eds). Diseases of the Breast. Philadelphia : Lippincott

metastases who would be at higher risk of recurrence and who might be candidates for complete lymph node dissection or adjuvant systemic therapy. A large meta-analysis, including 71 studies and 25,240 participants, estimated the risk of nodal recurrence after

improve clinical outcomes. Case Presentation A 39-year-old man was diagnosed with stage IV HER2 -amplified esophagogastric cancer in January 2012 after presenting with dysphagia and back pain demonstrating vertebral metastases. The patient had

of 1) increasing the sensitivity of long-term monitoring of thyroglobulin levels, 2) staging with posttherapy whole-body scan to detect local and distant metastases, and 3) facilitating the effectiveness of subsequent 131 I treatments if a large

prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors at a dose of 120 mg monthly 115 , 116 ( Table 2 ). Estrogen/Hormonal Therapy: Estrogen is an antiresorptive with proven antifracture efficacy, as demonstrated